TargetBeta
IL17A
interleukin 17A · also IL-17A, IL-17, CTLA8, IL17 · Interleukins
9 programs in company-led studies act on IL17A, from 7 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| secukinumabrule | Novartis | phase 4 | 1284 running | – | NCIt |
| vunakizumabrule | Jiangsu HengRui Medicine | phase 4 | 174 running | – | ChEMBL |
| ixekizumabrule | Eli Lilly | phase 4 | 383 running | – | ChEMBL |
| bimekizumabrule | UCB | phase 3 | 437 running | IL17F | ChEMBL |
| sonelokimabrule | MoonLake Immunotherapeutics | phase 3 | 124 running | IL17F | ChEMBL |
| SCT650Crule | Sinocelltech Group | phase 2 | 33 running | – | the studies' text |
| tibulizumabrule | Eli Lilly | phase 2 | 52 running | TNFSF13B | ChEMBL |
| simepdekinra | Eli Lilly | phase 2 | 70 running | – | a judged reading |
| UA026rule | Usynova Pharmaceuticals | phase 1 | 11 running | – | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- Psoriasis, 7 programs
- Arthritis, Psoriatic, 5 programs
- Hidradenitis Suppurativa, 5 programs
- Arthritis, Rheumatoid, 3 programs
- Axial Spondyloarthritis, 3 programs
- Spondylitis, Ankylosing, 3 programs
- Autoimmune Diseases, 1 program
- Graves Ophthalmopathy, 1 program
- Non-Radiographic Axial Spondyloarthritis, 1 program
- Scleroderma, Systemic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 21, 2026bimekizumab · UCB · phase 3 · NCT06921850
- Jan 4, 2027sonelokimab · MoonLake Immunotherapeutics · phase 3 · NCT06641089
- Mar 2027vunakizumab · Jiangsu HengRui Medicine · phase 4 · NCT06779097
- Mar 12, 2027SCT650C · Sinocelltech Group · phase 2 · NCT07244510
- May 2027tibulizumab · Eli Lilly · phase 2 · NCT06843239
- Jun 9, 2027ixekizumab · Eli Lilly · phase 4 · NCT07789964
- Feb 8, 2028secukinumab · Novartis · phase 4 · NCT05622708
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.